메뉴 건너뛰기




Volumn 15, Issue 5, 2018, Pages 273-291

Targeting the PI3K pathway in cancer: Are we making headway?

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 AMINO 8 [4 (2 HYDROXYETHOXY)CYCLOHEXYL] 6 (6 METHOXY 3 PYRIDINYL) 4 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 8 (6 METHOXY 3 PYRIDINYL) 3 METHYL 1 [4 (1 PIPERAZINYL) 3 (TRIFLUOROMETHYL)PHENYL] 1H IMIDAZO[4,5 C]QUINOLIN 2(3H) ONE; ABI 009; ADZ 2014; ANTINEOPLASTIC AGENT; APITOLISIB; AZD 8055; BIMIRALISIB; BUPARLISIB; CC 223; CH 5132799; COPANLISIB; DACTOLISIB; EVEROLIMUS; FULVESTRANT; GEDATOLISIB; IDELALISIB; LY 3023414; PICTILISIB; RAPAMYCIN; RIDAFOROLIMUS; SAPANISERTIB; SONOLISIB; TEMSIROLIMUS; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISTUSERTIB; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLINOPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-4-YL)PYRIMIDINE-5-CARBOXAMIDE; MTOR PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

EID: 85045583399     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2018.28     Document Type: Review
Times cited : (802)

References (151)
  • 1
    • 84896401739 scopus 로고    scopus 로고
    • Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
    • Polivka, J. Jr & Janku, F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol. Ther. 142, 164-175 (2014).
    • (2014) Pharmacol. Ther. , vol.142 , pp. 164-175
    • Polivka, J.1    Janku, F.2
  • 2
    • 67749122122 scopus 로고    scopus 로고
    • Targeting PI3K signalling in cancer: Opportunities, challenges and limitations
    • Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562 (2009).
    • (2009) Nat. Rev. Cancer , vol.9 , pp. 550-562
    • Engelman, J.A.1
  • 3
    • 68249093818 scopus 로고    scopus 로고
    • Targeting the phosphoinositide 3-kinase pathway in cancer
    • Liu, P., Cheng, H., Roberts, T. M. & Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644 (2009).
    • (2009) Nat. Rev. Drug Discov. , vol.8 , pp. 627-644
    • Liu, P.1    Cheng, H.2    Roberts, T.M.3    Zhao, J.J.4
  • 4
    • 84893249799 scopus 로고    scopus 로고
    • PI3K and cancer: Lessons, challenges and opportunities
    • Fruman, D. A. & Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13, 140-156 (2014).
    • (2014) Nat. Rev. Drug Discov. , vol.13 , pp. 140-156
    • Fruman, D.A.1    Rommel, C.2
  • 5
    • 85026529710 scopus 로고    scopus 로고
    • Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients
    • Janku, F. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients. Cancer Treat. Rev. 59, 93-101 (2017).
    • (2017) Cancer Treat. Rev. , vol.59 , pp. 93-101
    • Janku, F.1
  • 6
    • 84932631687 scopus 로고    scopus 로고
    • Drugging PI3K in cancer: Refining targets and therapeutic strategies
    • Yap, T. A., Bjerke, L., Clarke, P. A. & Workman, P. Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr. Opin. Pharmacol. 23, 98-107 (2015).
    • (2015) Curr. Opin. Pharmacol. , vol.23 , pp. 98-107
    • Yap, T.A.1    Bjerke, L.2    Clarke, P.A.3    Workman, P.4
  • 7
    • 84925545317 scopus 로고    scopus 로고
    • PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting
    • Thorpe, L. M., Yuzugullu, H. & Zhao, J. J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15, 7-24 (2015).
    • (2015) Nat. Rev. Cancer , vol.15 , pp. 7-24
    • Thorpe, L.M.1    Yuzugullu, H.2    Zhao, J.J.3
  • 8
    • 79952690921 scopus 로고    scopus 로고
    • PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
    • Janku, F. et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol. Cancer Ther. 10, 558-565 (2011).
    • (2011) Mol. Cancer Ther. , vol.10 , pp. 558-565
    • Janku, F.1
  • 9
    • 84895906492 scopus 로고    scopus 로고
    • Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors
    • Janku, F. et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 6, 377-387 (2014).
    • (2014) Cell Rep. , vol.6 , pp. 377-387
    • Janku, F.1
  • 10
    • 85023764187 scopus 로고    scopus 로고
    • AKT inhibition in solid tumors with AKT1 mutations
    • Hyman, D. M. et al. AKT inhibition in solid tumors with AKT1 mutations. J. Clin. Oncol. 35, 2251-2259 (2017).
    • (2017) J. Clin. Oncol. , vol.35 , pp. 2251-2259
    • Hyman, D.M.1
  • 11
    • 84867333656 scopus 로고    scopus 로고
    • Genome sequencing identifies a basis for everolimus sensitivity
    • Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012).
    • (2012) Science , vol.338 , pp. 221
    • Iyer, G.1
  • 12
    • 84968902640 scopus 로고    scopus 로고
    • Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma
    • Kwiatkowski, D. J. et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 22, 2445-2452 (2016).
    • (2016) Clin. Cancer Res. , vol.22 , pp. 2445-2452
    • Kwiatkowski, D.J.1
  • 13
    • 84907863603 scopus 로고    scopus 로고
    • Response and acquired resistance to everolimus in anaplastic thyroid cancer
    • Wagle, N. et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N. Engl. J. Med. 371, 1426-1433 (2014).
    • (2014) N. Engl. J. Med. , vol.371 , pp. 1426-1433
    • Wagle, N.1
  • 14
    • 78049510428 scopus 로고    scopus 로고
    • Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis
    • Krueger, D. A. et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801-1811 (2010).
    • (2010) N. Engl. J. Med. , vol.363 , pp. 1801-1811
    • Krueger, D.A.1
  • 15
    • 84960131361 scopus 로고    scopus 로고
    • RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors
    • Cheng, H. et al. RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors. Cancer Discov. 5, 1262-1270 (2015).
    • (2015) Cancer Discov. , vol.5 , pp. 1262-1270
    • Cheng, H.1
  • 16
    • 84899678098 scopus 로고    scopus 로고
    • A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity
    • Grabiner, B. C. et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 4, 554-563 (2014).
    • (2014) Cancer Discov , vol.4 , pp. 554-563
    • Grabiner, B.C.1
  • 17
    • 84942096399 scopus 로고    scopus 로고
    • Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer
    • Moulder, S. et al. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann. Oncol. 26, 1346-1352 (2015).
    • (2015) Ann. Oncol. , vol.26 , pp. 1346-1352
    • Moulder, S.1
  • 18
    • 79960127513 scopus 로고    scopus 로고
    • Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: Biologic rationale and implications for stem-cell research in breast cancer
    • Moulder, S. et al. Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J. Clin. Oncol. 29, e572-e575 (2011).
    • (2011) J. Clin. Oncol. , vol.29 , pp. e572-e575
    • Moulder, S.1
  • 19
    • 58249120506 scopus 로고    scopus 로고
    • Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance
    • Ihle, N. T. et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 69, 143-150 (2009).
    • (2009) Cancer Res. , vol.69 , pp. 143-150
    • Ihle, N.T.1
  • 20
    • 77955288855 scopus 로고    scopus 로고
    • Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
    • Di Nicolantonio, F. et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest. 120, 2858-2866 (2010).
    • (2010) J. Clin. Invest. , vol.120 , pp. 2858-2866
    • Di Nicolantonio, F.1
  • 21
    • 57349194139 scopus 로고    scopus 로고
    • Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
    • Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356 (2008).
    • (2008) Nat. Med. , vol.14 , pp. 1351-1356
    • Engelman, J.A.1
  • 22
    • 84863338519 scopus 로고    scopus 로고
    • PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
    • Janku, F. et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol. 30, 777-782 (2012).
    • (2012) J. Clin. Oncol. , vol.30 , pp. 777-782
    • Janku, F.1
  • 23
    • 84871968444 scopus 로고    scopus 로고
    • PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
    • Janku, F. et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 73, 276-284 (2013).
    • (2013) Cancer Res. , vol.73 , pp. 276-284
    • Janku, F.1
  • 24
    • 85010301206 scopus 로고    scopus 로고
    • A phase Ib study of alpelisib (BYL719), a PI3K-specific inhibitor, with letrozole in ER+/HER2-metastatic breast cancer
    • Mayer, I. A. et al. A phase Ib study of alpelisib (BYL719), a PI3K-specific inhibitor, with letrozole in ER+/HER2-metastatic breast cancer. Clin. Cancer Res. 23, 26-34 (2017).
    • (2017) Clin. Cancer Res. , vol.23 , pp. 26-34
    • Mayer, I.A.1
  • 25
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
    • (2007) N. Engl. J. Med. , vol.356 , pp. 2271-2281
    • Hudes, G.1
  • 26
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
    • Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008).
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1
  • 27
    • 84863078767 scopus 로고    scopus 로고
    • Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
    • Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520-529 (2012).
    • (2012) N. Engl. J. Med. , vol.366 , pp. 520-529
    • Baselga, J.1
  • 28
    • 84896692766 scopus 로고    scopus 로고
    • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
    • Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997-1007 (2014).
    • (2014) N. Engl. J. Med. , vol.370 , pp. 997-1007
    • Furman, R.R.1
  • 29
    • 84896693794 scopus 로고    scopus 로고
    • PI3K inhibition by idelalisib in patients with relapsed indolent lymphoma
    • Gopal, A. K. et al. PI3K inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008-1018 (2014).
    • (2014) N. Engl. J. Med. , vol.370 , pp. 1008-1018
    • Gopal, A.K.1
  • 30
    • 84874650275 scopus 로고    scopus 로고
    • Development of PI3K inhibitors: Lessons learned from early clinical trials
    • Rodon, J., Dienstmann, R., Serra, V. & Tabernero, J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10, 143-153 (2013).
    • (2013) Nat. Rev. Clin. Oncol. , vol.10 , pp. 143-153
    • Rodon, J.1    Dienstmann, R.2    Serra, V.3    Tabernero, J.4
  • 31
    • 85014844261 scopus 로고    scopus 로고
    • MTOR signaling in growth, metabolism, and disease
    • Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960-976 (2017).
    • (2017) Cell , vol.168 , pp. 960-976
    • Saxton, R.A.1    Sabatini, D.M.2
  • 33
    • 13844312400 scopus 로고    scopus 로고
    • Phosphorylation and regulation of Akt/ PKB by the rictor-mTOR complex
    • Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/ PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
    • (2005) Science , vol.307 , pp. 1098-1101
    • Sarbassov, D.D.1    Guertin, D.A.2    Ali, S.M.3    Sabatini, D.M.4
  • 34
    • 79851500081 scopus 로고    scopus 로고
    • Everolimus for advanced pancreatic neuroendocrine tumors
    • Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514-523 (2011).
    • (2011) N. Engl. J. Med. , vol.364 , pp. 514-523
    • Yao, J.C.1
  • 35
    • 84874746597 scopus 로고    scopus 로고
    • Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial
    • Bissler, J. J. et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381, 817-824 (2013).
    • (2013) Lancet , vol.381 , pp. 817-824
    • Bissler, J.J.1
  • 36
    • 84872088946 scopus 로고    scopus 로고
    • Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial
    • Franz, D. N. et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381, 125-132 (2013).
    • (2013) Lancet , vol.381 , pp. 125-132
    • Franz, D.N.1
  • 37
    • 84946607195 scopus 로고    scopus 로고
    • Nivolumab versus everolimus in advanced renal-cell carcinoma
    • Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015).
    • (2015) N. Engl. J. Med. , vol.373 , pp. 1803-1813
    • Motzer, R.J.1
  • 38
    • 84991063392 scopus 로고    scopus 로고
    • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial
    • Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 17, 917-927 (2016).
    • (2016) Lancet Oncol. , vol.17 , pp. 917-927
    • Choueiri, T.K.1
  • 39
    • 84960112967 scopus 로고    scopus 로고
    • Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study
    • Yao, J. C. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet 387, 968-977 (2016).
    • (2016) Lancet , vol.387 , pp. 968-977
    • Yao, J.C.1
  • 40
    • 84883063380 scopus 로고    scopus 로고
    • Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
    • Demetri, G. D. et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J. Clin. Oncol. 31, 2485-2492 (2013).
    • (2013) J. Clin. Oncol. , vol.31 , pp. 2485-2492
    • Demetri, G.D.1
  • 41
    • 84886413865 scopus 로고    scopus 로고
    • Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: Final results of a phase i trial
    • Gonzalez-Angulo, A. M. et al. Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin. Cancer Res. 19, 5474-5484 (2013).
    • (2013) Clin. Cancer Res. , vol.19 , pp. 5474-5484
    • Gonzalez-Angulo, A.M.1
  • 42
    • 33747819801 scopus 로고    scopus 로고
    • MTOR and cancer: Insights into a complex relationship
    • Sabatini, D. M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6, 729-734 (2006).
    • (2006) Nat. Rev. Cancer , vol.6 , pp. 729-734
    • Sabatini, D.M.1
  • 43
    • 79958696694 scopus 로고    scopus 로고
    • The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling
    • Hsu, P. P. et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-1322 (2011).
    • (2011) Science , vol.332 , pp. 1317-1322
    • Hsu, P.P.1
  • 44
    • 79958696336 scopus 로고    scopus 로고
    • Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling
    • Yu, Y. et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-1326 (2011).
    • (2011) Science , vol.332 , pp. 1322-1326
    • Yu, Y.1
  • 45
    • 84876276597 scopus 로고    scopus 로고
    • First-in-human phase i trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors [abstract]
    • Banerji, U. et al. First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors [abstract]. J. Clin. Oncol. 30 (Suppl.), 3004 (2012).
    • (2012) J. Clin. Oncol. , vol.30 , pp. 3004
    • Banerji, U.1
  • 47
    • 84866928171 scopus 로고    scopus 로고
    • Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
    • Naing, A. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br. J. Cancer 107, 1093-1099 (2012).
    • (2012) Br. J. Cancer , vol.107 , pp. 1093-1099
    • Naing, A.1
  • 48
    • 84961259098 scopus 로고    scopus 로고
    • TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase i dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom's macroglobulinemia
    • Ghobrial, I. M. et al. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom's macroglobulinemia. Am. J. Hematol. 91, 400-405 (2016).
    • (2016) Am. J. Hematol. , vol.91 , pp. 400-405
    • Ghobrial, I.M.1
  • 49
    • 84941907653 scopus 로고    scopus 로고
    • A phase 1, 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies [abstract]
    • Infante, J. R. et al. A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies [abstract]. Mol. Cancer Ther. 12 (Suppl.), C252 (2013).
    • (2013) Mol. Cancer Ther , pp. C252
    • Infante, J.R.1
  • 50
    • 84937706014 scopus 로고    scopus 로고
    • A phase i dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma
    • Bendell, J. C. et al. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer 121, 3481-3490 (2015).
    • (2015) Cancer , vol.121 , pp. 3481-3490
    • Bendell, J.C.1
  • 51
    • 84961393725 scopus 로고    scopus 로고
    • A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
    • Mateo, J. et al. A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. Br. J. Cancer 114, 889-896 (2016).
    • (2016) Br. J. Cancer , vol.114 , pp. 889-896
    • Mateo, J.1
  • 52
    • 85020030586 scopus 로고    scopus 로고
    • Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial
    • Baselga, J. et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 904-916 (2017).
    • (2017) Lancet Oncol. , vol.18 , pp. 904-916
    • Baselga, J.1
  • 53
    • 85040617674 scopus 로고    scopus 로고
    • Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): A randomised, double-blind, placebo-controlled, phase 3 trial
    • Di Leo, A. et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19, 87-100 (2018).
    • (2018) Lancet Oncol. , vol.19 , pp. 87-100
    • Di Leo, A.1
  • 54
    • 85019587899 scopus 로고    scopus 로고
    • A randomized adaptive phase II/III study of buparlisib, a pan-class i PI3K inhibitor, combined with paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4)
    • Martin, M. et al. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4). Ann. Oncol. 28, 313-320 (2017).
    • (2017) Ann. Oncol , vol.28 , pp. 313-320
    • Martin, M.1
  • 55
    • 84856071447 scopus 로고    scopus 로고
    • Phase I, dose-escalation study of BKM120, an oral pan-Class i PI3K inhibitor, in patients with advanced solid tumors
    • Bendell, J. C. et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30, 282-290 (2012).
    • (2012) J. Clin. Oncol. , vol.30 , pp. 282-290
    • Bendell, J.C.1
  • 56
    • 84923182481 scopus 로고    scopus 로고
    • A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors
    • Bedard, P. L. et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin. Cancer Res. 21, 730-738 (2015).
    • (2015) Clin. Cancer Res. , vol.21 , pp. 730-738
    • Bedard, P.L.1
  • 57
    • 84873079682 scopus 로고    scopus 로고
    • Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, single-arm, phase 2 study
    • Farley, J. et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, single-arm, phase 2 study. Lancet Oncol. 14, 134-140 (2013).
    • (2013) Lancet Oncol. , vol.14 , pp. 134-140
    • Farley, J.1
  • 58
    • 84964950086 scopus 로고    scopus 로고
    • Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): A randomised, double-blind, placebo-controlled, phase 2 trial
    • Krop, I. E. et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 17, 811-821 (2016).
    • (2016) Lancet Oncol. , vol.17 , pp. 811-821
    • Krop, I.E.1
  • 59
    • 85016766194 scopus 로고    scopus 로고
    • Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: Interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
    • Vuylsteke, P. et al. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. Ann. Oncol. 27, 2059-2066 (2016).
    • (2016) Ann. Oncol. , vol.27 , pp. 2059-2066
    • Vuylsteke, P.1
  • 60
    • 84892181757 scopus 로고    scopus 로고
    • Phase i safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class i PI3K inhibitor, in patients with advanced solid tumors
    • Shapiro, G. I. et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 20, 233-245 (2014).
    • (2014) Clin. Cancer Res. , vol.20 , pp. 233-245
    • Shapiro, G.I.1
  • 61
    • 84923108243 scopus 로고    scopus 로고
    • Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
    • Matulonis, U. et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol. Oncol. 136, 246-253 (2015).
    • (2015) Gynecol. Oncol. , vol.136 , pp. 246-253
    • Matulonis, U.1
  • 62
    • 84925503345 scopus 로고    scopus 로고
    • Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
    • Tolaney, S. et al. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Res. Treat. 149, 151-161 (2015).
    • (2015) Breast Cancer Res. Treat. , vol.149 , pp. 151-161
    • Tolaney, S.1
  • 63
    • 84925409338 scopus 로고    scopus 로고
    • Phase i dose-escalation study of pilaralisib ( SAR245408, XL147), a pan-class i PI3K inhibitor, in combination with erlotinib in patients with solid tumors
    • Soria, J. C. et al. Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors. Oncologist 20, 245-246 (2015).
    • (2015) Oncologist , vol.20 , pp. 245-246
    • Soria, J.C.1
  • 64
    • 84942290452 scopus 로고    scopus 로고
    • Phase i trial of the pan-PI3K inhibitor pilaralisib (SAR245408/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed/ refractory lymphoma
    • Brown, J. R. et al. Phase I trial of the pan-PI3K inhibitor pilaralisib (SAR245408/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed/ refractory lymphoma. Clin. Cancer Res. 21, 3160-3169 (2015).
    • (2015) Clin. Cancer Res. , vol.21 , pp. 3160-3169
    • Brown, J.R.1
  • 65
    • 85024391981 scopus 로고    scopus 로고
    • Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3-neutralizing human antibody SAR256212 in patients with solid tumors
    • Abramson, V. G. et al. Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3-neutralizing human antibody SAR256212 in patients with solid tumors. Clin. Cancer Res. 23, 3520-3528 (2017).
    • (2017) Clin. Cancer Res. , vol.23 , pp. 3520-3528
    • Abramson, V.G.1
  • 66
    • 85017466536 scopus 로고    scopus 로고
    • Phase i dose-escalation study of pilaralisib (SAR245408, XL147) in combination with paclitaxel and carboplatin in patients with solid tumors
    • Wheler, J. et al. Phase I dose-escalation study of pilaralisib (SAR245408, XL147) in combination with paclitaxel and carboplatin in patients with solid tumors. Oncologist 22, 377-e37 (2017).
    • (2017) Oncologist , vol.22 , pp. e337-e377
    • Wheler, J.1
  • 67
    • 85009147568 scopus 로고    scopus 로고
    • First-in-human phase i study of copanlisib (BAY 80-6946), an intravenous pan-class i phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
    • Patnaik, A. et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Ann. Oncol. 27, 1928-1940 (2016).
    • (2016) Ann. Oncol. , vol.27 , pp. 1928-1940
    • Patnaik, A.1
  • 68
    • 85037176051 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma
    • Dreyling, M. et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J. Clin. Oncol. 35, 3898-3905 (2017).
    • (2017) J. Clin. Oncol. , vol.35 , pp. 3898-3905
    • Dreyling, M.1
  • 69
    • 84864493357 scopus 로고    scopus 로고
    • A multicenter phase i trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors
    • Hong, D. S. et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 18, 4173-4182 (2012).
    • (2012) Clin. Cancer Res. , vol.18 , pp. 4173-4182
    • Hong, D.S.1
  • 70
    • 84883742774 scopus 로고    scopus 로고
    • A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
    • Bowles, D. W. et al. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br. J. Cancer 109, 1085-1092 (2013).
    • (2013) Br. J. Cancer , vol.109 , pp. 1085-1092
    • Bowles, D.W.1
  • 71
    • 85040044571 scopus 로고    scopus 로고
    • A multicenter phase i study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600 mutant solid tumors
    • Yam, C. et al. A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600 mutant solid tumors. Clin. Cancer Res. 24, 22-32 (2017).
    • (2017) Clin. Cancer Res. , vol.24 , pp. 22-32
    • Yam, C.1
  • 72
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
    • (2010) N. Engl. J. Med. , vol.363 , pp. 809-819
    • Flaherty, K.T.1
  • 73
    • 84902489842 scopus 로고    scopus 로고
    • A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer
    • Levy, B. et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. J. Thorac Oncol. 9, 1031-1035 (2014).
    • (2014) J. Thorac Oncol , vol.9 , pp. 1031-1035
    • Levy, B.1
  • 74
    • 84938677922 scopus 로고    scopus 로고
    • A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck
    • Bowles, D. W. et al. A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Invest. New Drugs 32, 1197-1203 (2014).
    • (2014) Invest. New Drugs , vol.32 , pp. 1197-1203
    • Bowles, D.W.1
  • 75
    • 84933180890 scopus 로고    scopus 로고
    • A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
    • Jimeno, A. et al. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Ann. Oncol. 26, 556-561 (2015).
    • (2015) Ann. Oncol. , vol.26 , pp. 556-561
    • Jimeno, A.1
  • 76
    • 84933178034 scopus 로고    scopus 로고
    • A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
    • Jimeno, A. et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncol. 51, 383-388 (2015).
    • (2015) Oral Oncol , vol.51 , pp. 383-388
    • Jimeno, A.1
  • 77
    • 84940778136 scopus 로고    scopus 로고
    • Phase II study of PX-866 in recurrent glioblastoma
    • Pitz, M. W. et al. Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol. 17, 1270-1274 (2015).
    • (2015) Neuro Oncol. , vol.17 , pp. 1270-1274
    • Pitz, M.W.1
  • 78
    • 84964671208 scopus 로고    scopus 로고
    • A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with metastatic colorectal carcinoma
    • Bowles, D. W. et al. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with metastatic colorectal carcinoma. Clin. Colorectal Cancer 15, 337-344. e2 (2016).
    • (2016) Clin. Colorectal Cancer , vol.15 , pp. 337-344e2
    • Bowles, D.W.1
  • 79
    • 84917683167 scopus 로고    scopus 로고
    • First-in-human study of CH5132799, an oral class i PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
    • Blagden, S. et al. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. Clin. Cancer Res. 20, 5908-5917 (2014).
    • (2014) Clin. Cancer Res. , vol.20 , pp. 5908-5917
    • Blagden, S.1
  • 80
    • 85045549584 scopus 로고    scopus 로고
    • A first-in-human phase i study of ZSTK474, an oral pan-PI3K inhibitor, in patients with advanced solid malignancies [abstract]
    • Lockhart, A. C. et al. A first-in-human phase I study of ZSTK474, an oral pan-PI3K inhibitor, in patients with advanced solid malignancies [abstract]. Mol. Cancer Ther. 12, B271 (2013).
    • (2013) Mol. Cancer Ther , vol.12 , pp. B271
    • Lockhart, A.C.1
  • 81
    • 84869505566 scopus 로고    scopus 로고
    • Phase i pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
    • Mahadevan, D. et al. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer 48, 3319-3327 (2012).
    • (2012) Eur. J. Cancer , vol.48 , pp. 3319-3327
    • Mahadevan, D.1
  • 82
    • 85026509256 scopus 로고    scopus 로고
    • A first-in-human, phase I, dose-escalation study of TAK-117, a selective PI3K isoform inhibitor, in patients with advanced solid malignancies
    • Juric, D. et al. A first-in-human, phase I, dose-escalation study of TAK-117, a selective PI3K isoform inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res. 23, 5015-5023 (2017).
    • (2017) Clin. Cancer Res. , vol.23 , pp. 5015-5023
    • Juric, D.1
  • 83
    • 84865562515 scopus 로고    scopus 로고
    • Phase i safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
    • Markman, B. et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann. Oncol. 23, 2399-2408 (2012).
    • (2012) Ann. Oncol. , vol.23 , pp. 2399-2408
    • Markman, B.1
  • 84
    • 84939949523 scopus 로고    scopus 로고
    • A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
    • Bendell, J. C. et al. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest. New Drugs 33, 463-471 (2015).
    • (2015) Invest. New Drugs , vol.33 , pp. 463-471
    • Bendell, J.C.1
  • 85
    • 84978708621 scopus 로고    scopus 로고
    • A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma
    • Carlo, M. I. et al. A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma. Oncologist 21, 787-788 (2016).
    • (2016) Oncologist , vol.21 , pp. 787-788
    • Carlo, M.I.1
  • 86
    • 85016833054 scopus 로고    scopus 로고
    • Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
    • Massard, C. et al. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. Eur. J. Cancer 76, 36-44 (2017).
    • (2017) Eur. J. Cancer , vol.76 , pp. 36-44
    • Massard, C.1
  • 87
    • 84975089435 scopus 로고    scopus 로고
    • Phase i study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors
    • Dolly, S. O. et al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 22, 2874-2884 (2016).
    • (2016) Clin. Cancer Res. , vol.22 , pp. 2874-2884
    • Dolly, S.O.1
  • 88
    • 84987837583 scopus 로고    scopus 로고
    • A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
    • Makker, V. et al. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer 122, 3519-3528 (2016).
    • (2016) Cancer , vol.122 , pp. 3519-3528
    • Makker, V.1
  • 89
    • 84970024646 scopus 로고    scopus 로고
    • Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma
    • Powles, T. et al. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 34, 1660-1668 (2016).
    • (2016) J. Clin. Oncol. , vol.34 , pp. 1660-1668
    • Powles, T.1
  • 90
    • 84927624149 scopus 로고    scopus 로고
    • First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer
    • Shapiro, G. I. et al. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin. Cancer Res. 21, 1888-1895 (2015).
    • (2015) Clin. Cancer Res. , vol.21 , pp. 1888-1895
    • Shapiro, G.I.1
  • 91
    • 84904622446 scopus 로고    scopus 로고
    • Phase i study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
    • Britten, C. D. et al. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Invest. New Drugs 32, 510-517 (2014).
    • (2014) Invest. New Drugs , vol.32 , pp. 510-517
    • Britten, C.D.1
  • 92
    • 84947879756 scopus 로고    scopus 로고
    • A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer
    • Moore, K. N. et al. A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer. J. Clin. Oncol. 33, 11075-11075 (2015).
    • (2015) J. Clin. Oncol. , vol.33 , pp. 11075
    • Moore, K.N.1
  • 93
    • 85020170041 scopus 로고    scopus 로고
    • A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final de results [abstract]
    • Kristeleit, R. S. et al. A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: final DE results [abstract]. J. Clin. Oncol. 33 (Suppl.), 2592 (2015).
    • (2015) J. Clin. Oncol. , vol.33 , pp. 2592
    • Kristeleit, R.S.1
  • 94
    • 85045547716 scopus 로고    scopus 로고
    • Identification of NOTCH1 inactivating mutation as a therapeutic vulnerability to PI3K/mTOR pathway inhibition in head and neck squamous cell carcinoma (HNSCC) [abstract]
    • Sambandam, V. et al. Identification of NOTCH1 inactivating mutation as a therapeutic vulnerability to PI3K/mTOR pathway inhibition in head and neck squamous cell carcinoma (HNSCC) [abstract]. Cancer Res. 77 (Suppl.), 2992 (2017).
    • (2017) Cancer Res. , vol.77 , pp. 2992
    • Sambandam, V.1
  • 95
    • 0038549067 scopus 로고    scopus 로고
    • PI3K in lymphocyte development, differentiation and activation
    • Okkenhaug, K. & Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3, 317-330 (2003).
    • (2003) Nat. Rev. Immunol. , vol.3 , pp. 317-330
    • Okkenhaug, K.1    Vanhaesebroeck, B.2
  • 96
    • 84925500147 scopus 로고    scopus 로고
    • Convergent loss of PTEN leads to clinical resistance to a PI(3)K inhibitor
    • Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)K inhibitor. Nature 518, 240-244 (2015).
    • (2015) Nature , vol.518 , pp. 240-244
    • Juric, D.1
  • 97
    • 85045539353 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: Results from the first-in-human study
    • Juric, D. et al. Phosphatidylinositol 3-kinase-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J. Clin. Oncol. https://doi. org/10. 1200/ JCO. 2017. 72. 7107 (2018).
    • (2018) J. Clin. Oncol.
    • Juric, D.1
  • 98
    • 84954518142 scopus 로고    scopus 로고
    • Phase i study of the PI3K alpha inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer [abstract]
    • Janku, F. et al. Phase I study of the PI3K alpha inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer [abstract]. Cancer Res. 75 (Suppl.), PD5-5 (2015).
    • (2015) Cancer Res. , vol.75 , pp. PD5-5
    • Janku, F.1
  • 99
    • 81755162797 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer
    • Miller, T. W., Balko, J. M. & Arteaga, C. L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J. Clin. Oncol. 29, 4452-4461 (2011).
    • (2011) J. Clin. Oncol. , vol.29 , pp. 4452-4461
    • Miller, T.W.1    Balko, J.M.2    Arteaga, C.L.3
  • 100
    • 84928186818 scopus 로고    scopus 로고
    • PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
    • Bosch, A. et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci. Transl Med. 7, 283ra51 (2015).
    • (2015) Sci. Transl Med. , vol.7 , pp. 283ra51
    • Bosch, A.1
  • 101
    • 85020402539 scopus 로고    scopus 로고
    • A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer
    • van Geel, R. et al. A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov. 7, 610-619 (2017).
    • (2017) Cancer Discov , vol.7 , pp. 610-619
    • Van Geel, R.1
  • 102
    • 84863230465 scopus 로고    scopus 로고
    • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    • Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
    • (2012) Nature , vol.483 , pp. 100-103
    • Prahallad, A.1
  • 103
    • 84873360893 scopus 로고    scopus 로고
    • Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
    • Mao, M. et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin. Cancer Res. 19, 657-667 (2013).
    • (2013) Clin. Cancer Res. , vol.19 , pp. 657-667
    • Mao, M.1
  • 104
    • 84939864059 scopus 로고    scopus 로고
    • Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
    • Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726-736 (2015).
    • (2015) N. Engl. J. Med. , vol.373 , pp. 726-736
    • Hyman, D.M.1
  • 105
    • 85018510810 scopus 로고    scopus 로고
    • Phase i dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors
    • Juric, D. et al. Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors. Cancer Discov. 7, 704-715 (2017).
    • (2017) Cancer Discov. , vol.7 , pp. 704-715
    • Juric, D.1
  • 106
    • 85036497908 scopus 로고    scopus 로고
    • SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors [abstract]
    • Baselga, J. et al. SANDPIPER: phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors [abstract]. J. Clin. Oncol. 35 (Suppl.), TPS1119 (2017).
    • (2017) J. Clin. Oncol. , vol.35 , pp. TPS1119
    • Baselga, J.1
  • 107
    • 85038638605 scopus 로고    scopus 로고
    • Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/ HER2-negative early breast cancer (EBC) [abstract]
    • Saura, C. et al. Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/ HER2-negative early breast cancer (EBC) [abstract]. Ann. Oncol. 28 (Suppl.), LBA9 (2017).
    • (2017) Ann. Oncol. , vol.28 , pp. LBA9
    • Saura, C.1
  • 108
    • 85045547636 scopus 로고    scopus 로고
    • ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models [abstract]
    • Thompson, S. K. et al. ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models [abstract]. Mol. Cancer Ther. 14 (Suppl. 2), B100 (2015).
    • (2015) Mol. Cancer Ther. , vol.14 , pp. B100
    • Thompson, S.K.1
  • 109
    • 49649087385 scopus 로고    scopus 로고
    • Essential roles of PI(3)K-p110 in cell growth, metabolism and tumorigenesis
    • Jia, S. et al. Essential roles of PI(3)K-p110 in cell growth, metabolism and tumorigenesis. Nature 454, 776-779 (2008).
    • (2008) Nature , vol.454 , pp. 776-779
    • Jia, S.1
  • 110
    • 84863833204 scopus 로고    scopus 로고
    • Functional characterization of an isoform-selective inhibitor of PI3K-p110 as a potential anticancer agent
    • Ni, J. et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110 as a potential anticancer agent. Cancer Discov. 2, 425-433 (2012).
    • (2012) Cancer Discov. , vol.2 , pp. 425-433
    • Ni, J.1
  • 111
    • 85032305458 scopus 로고    scopus 로고
    • A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors
    • Mateo, J. et al. A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 23, 5981-5992 (2017).
    • (2017) Clin. Cancer Res. , vol.23 , pp. 5981-5992
    • Mateo, J.1
  • 112
    • 85036497908 scopus 로고    scopus 로고
    • A first in human phase i study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib or abiraterone acetate [abstract]
    • Hansen, A. R. et al. A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib or abiraterone acetate [abstract]. J. Clin. Oncol. 35 (Suppl.), 2570 (2017).
    • (2017) J. Clin. Oncol. , vol.35 , pp. 2570
    • Hansen, A.R.1
  • 113
    • 85040239288 scopus 로고    scopus 로고
    • First-in-human trial of the PI3K-selective inhibitor SAR260301 in patients with advanced solid tumors
    • Bédard, P. L. et al. First-in-human trial of the PI3K-selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer 124, 315-324 (2018).
    • (2018) Cancer , vol.124 , pp. 315-324
    • Bédard, P.L.1
  • 114
    • 47049113462 scopus 로고    scopus 로고
    • Role of PI3K and PI3K in inflammatory arthritis and tissue localization of neutrophils
    • Randis, T. M., Puri, K. D., Zhou, H. & Diacovo, T. G. Role of PI3K and PI3K in inflammatory arthritis and tissue localization of neutrophils. Eur. J. Immunol. 38, 1215-1224 (2008).
    • (2008) Eur. J. Immunol. , vol.38 , pp. 1215-1224
    • Randis, T.M.1    Puri, K.D.2    Zhou, H.3    Diacovo, T.G.4
  • 115
    • 54049102066 scopus 로고    scopus 로고
    • PI3Kgamma (PI3K) is essential for efficient induction of CXCR3 on activated T cells
    • Barbi, J. et al. PI3Kgamma (PI3K) is essential for efficient induction of CXCR3 on activated T cells. Blood 112, 3048-3051 (2008).
    • (2008) Blood , vol.112 , pp. 3048-3051
    • Barbi, J.1
  • 116
    • 84995948061 scopus 로고    scopus 로고
    • Overcoming resistance to checkpoint blockade therapy by targeting PI3K in myeloid cells
    • De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K in myeloid cells. Nature 539, 443-447 (2016).
    • (2016) Nature , vol.539 , pp. 443-447
    • De Henau, O.1
  • 117
    • 85043783382 scopus 로고    scopus 로고
    • IPI-549-01-a phase 1/1b, first-in-human study of IPI-549, a PI3K-inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors [abstract]
    • Tolcher, A. et al. IPI-549-01-a phase 1/1b, first-in-human study of IPI-549, a PI3K-inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors [abstract]. Cancer Res. 77 (Suppl.), CT089 (2017).
    • (2017) Cancer Res. , vol.77 , pp. CT089
    • Tolcher, A.1
  • 118
    • 84978389613 scopus 로고    scopus 로고
    • Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
    • Lampson, B. L. et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128, 195-203 (2016).
    • (2016) Blood , vol.128 , pp. 195-203
    • Lampson, B.L.1
  • 119
    • 84974604103 scopus 로고    scopus 로고
    • Phase 2 study of idelalisib and entospletinib: Pneumonitis limits combination therapy in relapsed refractory CLL and NHL
    • Barr, P. M. et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood 127, 2411-2415 (2016).
    • (2016) Blood , vol.127 , pp. 2411-2415
    • Barr, P.M.1
  • 120
    • 84927673054 scopus 로고    scopus 로고
    • FDA approval: Idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma
    • Miller, B. W. et al. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin. Cancer Res. 21, 1525-1529 (2015).
    • (2015) Clin. Cancer Res. , vol.21 , pp. 1525-1529
    • Miller, B.W.1
  • 121
    • 85010951468 scopus 로고    scopus 로고
    • Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial
    • Zelenetz, A. D. et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 18, 297-311 (2017).
    • (2017) Lancet Oncol. , vol.18 , pp. 297-311
    • Zelenetz, A.D.1
  • 123
    • 84924664474 scopus 로고    scopus 로고
    • Duvelisib (IPI-145), a PI3K-, inhibitor, is clinically active in patients with relapsed/ refractory chronic lymphocytic leukemia
    • O'Brien, S. et al. Duvelisib (IPI-145), a PI3K-, inhibitor, is clinically active in patients with relapsed/ refractory chronic lymphocytic leukemia. Blood 124, 3334-3334 (2014).
    • (2014) Blood , vol.124 , pp. 3334
    • O'Brien, S.1
  • 124
    • 84930330798 scopus 로고    scopus 로고
    • Clinical activity of duvelisib (IPI-145), a phosphoinositide-3-kinase-, inhibitor, in patients previously treated with ibrutinib
    • Porcu, P. et al. Clinical activity of duvelisib (IPI-145), a phosphoinositide-3-kinase-, inhibitor, in patients previously treated with ibrutinib. Blood 124, 3335-3335 (2014).
    • (2014) Blood , vol.124 , pp. 3335
    • Porcu, P.1
  • 125
    • 84927776088 scopus 로고    scopus 로고
    • A phase 1 evaluation of duvelisib (IPI-145), a PI3K-, inhibitor, in patients with relapsed/refractory iNHL
    • Flinn, I. et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-, inhibitor, in patients with relapsed/refractory iNHL. Blood 124, 802-802 (2014).
    • (2014) Blood , vol.124 , pp. 802
    • Flinn, I.1
  • 126
    • 84927728003 scopus 로고    scopus 로고
    • Duvelisib (IPI-145), a phosphoinositide-3-kinase-, inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma
    • Horwitz, S. M. et al. Duvelisib (IPI-145), a phosphoinositide-3-kinase-, inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma. Blood 124, 803-803 (2014).
    • (2014) Blood , vol.124 , pp. 803
    • Horwitz, S.M.1
  • 127
    • 84931957197 scopus 로고    scopus 로고
    • An open-label, phase Ib study of duvelisib (IPI-145) in combination with bendamustine, rituximab or bendamustine/rituximab in select subjects with lymphoma or chronic lymphocytic leukemia
    • Flinn, I. et al. An open-label, phase Ib study of duvelisib (IPI-145) in combination with bendamustine, rituximab or bendamustine/rituximab in select subjects with lymphoma or chronic lymphocytic leukemia. Blood 124, 4422-4422 (2014).
    • (2014) Blood , vol.124 , pp. 4422
    • Flinn, I.1
  • 128
    • 84909943632 scopus 로고    scopus 로고
    • First-in-human study of AMG319, a highly selective, small molecule inhibitor of PI3K, in adult patients with relapsed or refractory lymphoid malignancies
    • Glenn, M. et al. First-in-human study of AMG 319, a highly selective, small molecule inhibitor of PI3K, in adult patients with relapsed or refractory lymphoid malignancies. Blood 122, 678-678 (2013).
    • (2013) Blood , vol.122 , pp. 678
    • Glenn, M.1
  • 129
    • 83255162603 scopus 로고    scopus 로고
    • First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors
    • Yap, T. A. et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 29, 4688-4695 (2011).
    • (2011) J. Clin. Oncol. , vol.29 , pp. 4688-4695
    • Yap, T.A.1
  • 130
    • 84978120246 scopus 로고    scopus 로고
    • Adaptive randomization of veliparib-carboplatin treatment in breast cancer
    • Rugo, H. S. et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N. Engl. J. Med. 375, 23-34 (2016).
    • (2016) N. Engl. J. Med. , vol.375 , pp. 23-34
    • Rugo, H.S.1
  • 131
    • 84978076672 scopus 로고    scopus 로고
    • Adaptive randomization of neratinib in early breast cancer
    • Park, J. W. et al. Adaptive randomization of neratinib in early breast cancer. N. Engl. J. Med. 375, 11-22 (2016).
    • (2016) N. Engl. J. Med. , vol.375 , pp. 11-22
    • Park, J.W.1
  • 132
    • 84945587095 scopus 로고    scopus 로고
    • Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 trial [abstract]
    • Tripathy, D. et al. Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: graduation results from the I-SPY 2 trial [abstract]. J. Clin. Oncol. 33, 524 (2015).
    • (2015) J. Clin. Oncol. , vol.33 , pp. 524
    • Tripathy, D.1
  • 133
    • 84992386844 scopus 로고    scopus 로고
    • The BATTLE-2 study: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer
    • Papadimitrakopoulou, V. et al. The BATTLE-2 study: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 34, 3638-3647 (2016).
    • (2016) J. Clin. Oncol. , vol.34 , pp. 3638-3647
    • Papadimitrakopoulou, V.1
  • 134
    • 84867506516 scopus 로고    scopus 로고
    • Biomarkers of response to Akt inhibitor MK-2206 in breast cancer
    • Sangai, T. et al. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin. Cancer Res. 18, 5816-5828 (2012).
    • (2012) Clin. Cancer Res. , vol.18 , pp. 5816-5828
    • Sangai, T.1
  • 135
    • 84930402659 scopus 로고    scopus 로고
    • SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer
    • Gonzalez-Angulo, A. M. et al. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J. Natl Cancer Inst. 107, dju493 (2015).
    • (2015) J. Natl Cancer Inst. , vol.107 , pp. dju493
    • Gonzalez-Angulo, A.M.1
  • 136
    • 84918538482 scopus 로고    scopus 로고
    • Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers
    • Yap, T. A. et al. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin. Cancer Res. 20, 5672-5685 (2014).
    • (2014) Clin. Cancer Res. , vol.20 , pp. 5672-5685
    • Yap, T.A.1
  • 137
    • 85014544526 scopus 로고    scopus 로고
    • Results from a phase 1 study of ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma [abstract]
    • Tolcher, A. et al. Results from a phase 1 study of ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma [abstract]. Eur. J. Cancer 51 (Suppl. 3), 338 (2015).
    • (2015) Eur. J. Cancer , vol.51 , pp. 338
    • Tolcher, A.1
  • 138
    • 84949035119 scopus 로고    scopus 로고
    • Targeting AKT1-E17K and the PI3K/AKT pathway with an allosteric AKT inhibitor, ARQ 092
    • Yu, Y. et al. Targeting AKT1-E17K and the PI3K/AKT pathway with an allosteric AKT inhibitor, ARQ 092. PLoS ONE 10, e0140479 (2015).
    • (2015) PLoS ONE , vol.10 , pp. e0140479
    • Yu, Y.1
  • 139
    • 84995495504 scopus 로고    scopus 로고
    • BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models
    • Politz, O. et al. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. Int. J. Cancer 140, 449-459 (2017).
    • (2017) Int. J. Cancer , vol.140 , pp. 449-459
    • Politz, O.1
  • 140
    • 80054747639 scopus 로고    scopus 로고
    • Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase i first-in-human study [abstract]
    • Burris, H. A. et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study [abstract]. J. Clin. Oncol. 29 (Suppl.), 3003 (2011).
    • (2011) J. Clin. Oncol. , vol.29 , pp. 3003
    • Burris, H.A.1
  • 141
    • 85009376465 scopus 로고    scopus 로고
    • A first-in-human phase i study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors
    • Saura, C. et al. A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov. 7, 102-113 (2017).
    • (2017) Cancer Discov , vol.7 , pp. 102-113
    • Saura, C.1
  • 142
    • 85027258099 scopus 로고    scopus 로고
    • Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    • Kim, S. B. et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 18, 1360-1372 (2017).
    • (2017) Lancet Oncol. , vol.18 , pp. 1360-1372
    • Kim, S.B.1
  • 143
    • 85045540606 scopus 로고    scopus 로고
    • A phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers
    • Banerji, U. et al. A phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clin. Cancer Res. https://doi. org/10. 1158/1078-0432. CCR-17-2260 (2017).
    • (2017) Clin. Cancer Res.
    • Banerji, U.1
  • 144
    • 85014543162 scopus 로고    scopus 로고
    • A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase i trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers [abstract]
    • Banerji, U. et al. A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers [abstract]. J. Clin. Oncol. 33 (Suppl.), 2500 (2015).
    • (2015) J. Clin. Oncol. , vol.33 , pp. 2500
    • Banerji, U.1
  • 145
    • 85045569067 scopus 로고    scopus 로고
    • A first in human, dose escalation trial of MSC2363318A-a dual p70S6K/ Akt inhibitor, for patients with advanced malignancies [abstract]
    • Tsimberidou, A. M. et al. A first in human, dose escalation trial of MSC2363318A-a dual p70S6K/ Akt inhibitor, for patients with advanced malignancies [abstract]. Ann. Oncol. 26 (Suppl. 2), P5. 01 (2015).
    • (2015) Ann. Oncol , vol.26 , pp. P501
    • Tsimberidou, A.M.1
  • 146
    • 79960927451 scopus 로고    scopus 로고
    • PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
    • Janku, F. et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE 6, e22769 (2011).
    • (2011) PLoS ONE , vol.6 , pp. e22769
    • Janku, F.1
  • 147
    • 84890520181 scopus 로고    scopus 로고
    • Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
    • Ganesan, P. et al. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol. Cancer Ther. 12, 2857-2863 (2013).
    • (2013) Mol. Cancer Ther. , vol.12 , pp. 2857-2863
    • Ganesan, P.1
  • 148
    • 84866070768 scopus 로고    scopus 로고
    • Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase 1 clinical trials
    • Dienstmann, R. et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase 1 clinical trials. Mol. Cancer Ther. 11, 2062-2071 (2012).
    • (2012) Mol. Cancer Ther. , vol.11 , pp. 2062-2071
    • Dienstmann, R.1
  • 149
    • 84928254065 scopus 로고    scopus 로고
    • Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
    • McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl Med. 7, 283ra54 (2015).
    • (2015) Sci. Transl Med. , vol.7 , pp. 283ra54
    • McGranahan, N.1
  • 150
    • 84936890500 scopus 로고    scopus 로고
    • Subclonal diversification of primary breast cancer revealed by multiregion sequencing
    • Yates, L. R. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751-759 (2015).
    • (2015) Nat. Med. , vol.21 , pp. 751-759
    • Yates, L.R.1
  • 151
    • 85019668203 scopus 로고    scopus 로고
    • Tracking the evolution of non-small-cell lung cancer
    • Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109-2121 (2017).
    • (2017) N. Engl. J. Med. , vol.376 , pp. 2109-2121
    • Jamal-Hanjani, M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.